Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
21
INAB Quote, Financials, Valuation and Earnings
Last price:
$0.24
Seasonality move
:
-39.87%
Day range:
$0.23 - $0.26
52-week range:
$0.22 - $1.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.03x
Volume:
607.6K
Avg. volume:
641.9K
1-year change:
-80.65%
Market cap:
$17.4M
Revenue:
--
EPS (TTM):
-$0.75
Analysts' Opinion
-
Consensus RatingIN8bio has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, IN8bio has an estimated upside of 1879.17% from its current price of $0.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.24.
Fair Value
-
According to the consensus of 2 analysts, IN8bio has 1879.17% upside to fair value with a price target of -- per share.
INAB vs. S&P 500
-
Over the past 5 trading days, IN8bio has underperformed the S&P 500 by -16.23% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
IN8bio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IN8bio has grown year-over-year revenues for 0 quarters straight. In the most recent quarter IN8bio reported revenues of --.
Earnings Growth
-
IN8bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter IN8bio reported earnings per share of -$0.15.
Enterprise value:
13.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.53x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$26.6M | -$30.2M | -$31.3M | -$7.2M | -$6M | |
| EBITDA | -$25.6M | -$28M | -$28.7M | -$6.5M | -$5.4M | |
| Diluted EPS | -$1.36 | -$1.11 | -$0.75 | -$0.23 | -$0.15 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $43.9M | $29.7M | $16.5M | $6.7M | |
| Total Assets | -- | $47.1M | $38.4M | $26.2M | $16M | |
| Current Liabilities | -- | $2.2M | $4.9M | $4.7M | $3.6M | |
| Total Liabilities | -- | $4.1M | $8.8M | $8.5M | $7.4M | |
| Total Equity | -- | $43M | $29.6M | $17.8M | $8.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.3M | -$26.4M | -$25M | -$5.7M | -$6.1M | |
| Cash From Investing | -$2.6M | -$1.8M | -$226K | -$77K | -- | |
| Cash From Financing | $8M | $13.4M | $16.3M | $1.7M | -$105K | |
| Free Cash Flow | -$20.9M | -$28.2M | -$25.2M | -$5.8M | -$6.1M | |
INAB
Sector
Market Cap
$17.4M
$45.6M
Price % of 52-Week High
12.44%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-80.65%
-31.35%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.27
200-day SMA
Sell
Level
$0.70
Bollinger Bands (100)
Sell
Level
0.23 - 0.51
Chaikin Money Flow
Sell
Level
-18.3M
20-day SMA
Sell
Level
$0.30
Relative Strength Index (RSI14)
Sell
Level
37.80
ADX Line
Sell
Level
18.24
Williams %R
Buy
Level
-92.5212
50-day SMA
Sell
Level
$0.30
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
300M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Stock Forecast FAQ
In the current month, INAB has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The INAB average analyst price target in the past 3 months is --.
-
Where Will IN8bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that IN8bio share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About IN8bio?
Analysts are divided on their view about IN8bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IN8bio is a Sell and believe this share price will drop from its current level to --.
-
What Is IN8bio's Price Target?
The price target for IN8bio over the next 1-year time period is forecast to be -- according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is INAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IN8bio is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of INAB?
You can purchase shares of IN8bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IN8bio shares.
-
What Is The IN8bio Share Price Today?
IN8bio was last trading at $0.24 per share. This represents the most recent stock quote for IN8bio. Yesterday, IN8bio closed at $0.24 per share.
-
How To Buy IN8bio Stock Online?
In order to purchase IN8bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
52
TSLL alert for Dec 24
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
31
SOXL alert for Dec 24
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.
